血清GFAP与UCH-L1预测心脏骤停昏迷患者神经功能预后
该研究纳入717例心脏骤停后昏迷患者,在骤停后24、48、72小时检测血清GFAP与UCH-L1,以6个月随访时脑功能分级量表(CPC)1-2分为良好、3-5分为不良。结果显示GFAP单独AUROC 0.88-0.89、UCH-L1单独0.85-0.87、两者联合0.90-0.91,联合模型在所有时间点均优于单独指标及NSE(AUROC 0.75-0.85)。在特异度≥95%时,联合模型24小时预测不良预后的敏感度高于NSE,48与72小时敏感度相似。作者认为联合检测可能对心脏骤停后早期预后判断有特殊价值。
要点
- 心脏骤停后24、48、72小时血清GFAP与UCH-L1联合模型预测6个月不良神经预后(CPC3-5)AUROC 0.90-0.91。
- 联合模型在所有时间点均优于单独GFAP(AUROC 0.88-0.89)、单独UCH-L1(AUROC 0.85-0.87)及NSE(AUROC 0.75-0.85)。
- 特异度≥95%时,联合模型24小时预测不良预后的敏感度高于NSE,48与72小时与NSE相似。
- 欧洲复苏委员会预后指南目前唯一推荐的血清标志物为神经元特异性烯醇化酶(NSE),但NSE存在局限性。
- 作者认为GFAP与UCH-L1联合可能对心脏骤停后早期预后判断有特殊价值。
适用人群与场景
- 心脏骤停后昏迷患者,共纳入717例。
诊断标准与关键阈值
- 神经功能以脑功能分级量表(CPC)评估,6个月随访时CPC1-2为良好、CPC3-5为不良。
研究设计与关键结果
- 研究纳入717例心脏骤停患者,于骤停后24、48、72小时采集血清GFAP与UCH-L1,主要终点为6个月CPC二分结局。
- GFAP单独在各时间点区分良好与不良神经预后AUROC 0.88-0.89,UCH-L1单独AUROC 0.85-0.87,两者联合AUROC 0.90-0.91。
- 联合模型在所有时间点均优于单独GFAP、单独UCH-L1及NSE(AUROC 0.75-0.85)。
- 特异度≥95%时,联合模型24小时预测不良预后的敏感度高于NSE,48与72小时敏感度与NSE相似。
证据类型、等级与局限
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为GFAP与UCH-L1联合可能对心脏骤停后早期预后判断有特殊价值,在早期预后判断中表现显著优于目前推荐的标志物NSE。
- 欧洲复苏委员会预后指南目前唯一推荐的血清标志物为NSE,但NSE存在局限性。
指南或共识出处
- 欧洲复苏委员会(European Resuscitation Council)预后指南。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Neurological outcome prediction is crucial early after cardiac arrest. Serum biomarkers released from brain cells after hypoxic-ischaemic injury may aid in outcome prediction. The only serum biomarker presently recommended in the European Resuscitation Council prognostication guidelines is neuron-specific enolase (NSE), but NSE has limitations. In this study, we therefore analyzed the outcome predictive accuracy of the serum biomarkers glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) in patients after cardiac arrest.
METHODS: Serum GFAP and UCH-L1 were collected at 24, 48 and 72 h after cardiac arrest. The primary outcome was neurological function at 6-month follow-up assessed by the cerebral performance category scale (CPC), dichotomized into good (CPC1-2) and poor (CPC3-5). Prognostic accuracies were tested with receiver-operating characteristics by calculating the area under the receiver-operating curve (AUROC) and compared to the AUROC of NSE.
RESULTS: 717 patients were included in the study. GFAP and UCH-L1 discriminated between good and poor neurological outcome at all time-points when used alone (AUROC GFAP 0.88-0.89; UCH-L1 0.85-0.87) or in combination (AUROC 0.90-0.91). The combined model was superior to GFAP and UCH-L1 separately and NSE (AUROC 0.75-0.85) at all time-points. At specificities ≥95%, the combined model predicted poor outcome with a higher sensitivity than NSE at 24 h and with similar sensitivities at 48 and 72 h.
CONCLUSION: GFAP and UCH-L1 predicted poor neurological outcome with high accuracy. Their combination may be of special interest for early prognostication after cardiac arrest where it performed significantly better than the currently recommended biomarker NSE.
参考来源
- Ebner F, Moseby-Knappe M, Mattsson-Carlgren N, et al. Serum GFAP and UCH-L1 for the prediction of neurological outcome in comatose cardiac arrest patients. Resuscitation. 2020. PMID: 32445783. doi:10.1016/j.resuscitation.2020.05.016
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。